title: Effects of desoxycorticosterone pivalate administration on blood pressure in dogs with primary hypoadrenocorticism.
abstract: A study was designed to evaluate the effects of desoxycorticosterone pivalate (DOCP) on blood pressure in 8 dogs with primary hypoadrenocorticism, and to attempt to identify other factors that might suggest overdosage of the drug. In 4 dogs, primary hypoadrenocorticism had been diagnosed immediately before entry of the dog into the study, and the dogs had not received any mineralocorticoid supplementation. In the other 4 dogs, primary hypoadrenocorticism had been diagnosed 1 to 6 years previously, and dogs were being treated with DOCP at the time of entry into the study. In all 8 dogs, DOCP (2.2 mg/kg of body weight, IM) was administered on days 0, 30, 60, and 90 of the study; each dog was examined on days 0, 30, 60, 75, 90, and 105. At the time of each visit, a medical history was obtained, a complete physical examination and serum biochemical analyses were performed, and body weight and blood pressure were measured. Doppler-shift ultrasonic sphygmomanometry was used to indirectly record systemic systolic and diastolic pressures. None of the dogs developed hypernatremia or hypokalemia or any clinical signs suggestive of hypoadrenocorticism during the study. However, in 6 dogs (3 that had not been previously treated with mineralocorticoids and 3 that had been), there was a significant increase in body weight over the course of the study. Compared with baseline (day 0) arterial blood pressure, neither systolic nor diastolic blood pressure was significantly increased during the study, and all systolic and diastolic blood pressure measurements were within reference ranges at all evaluation times.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Department of Medicine, Animal Medical Center, New York, NY 10021, USA.
authors.forename: A J
authors.initials: AJ
authors.lastname: Kaplan
authors.forename: M E
authors.initials: ME
authors.lastname: Peterson
mesh_terms: D000309:Adrenal Insufficiency / Q000188:drug therapy / Q000503:physiopathology / Q000662:veterinary*; D000818:Animals; D001794:Blood Pressure / Q000187:drug effects*; D001795:Blood Pressure Determination / Q000379:methods / Q000662:veterinary; D001835:Body Weight / Q000187:drug effects; D003900:Desoxycorticosterone / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D004283:Dog Diseases / Q000188:drug therapy* / Q000503:physiopathology; D004285:Dogs; D005260:Female; D008297:Male; D011188:Potassium / Q000097:blood; D012964:Sodium / Q000097:blood
chemical_list: C019323:deoxycortone pivalate; D003900:Desoxycorticosterone; D012964:Sodium; D011188:Potassium